Clinical Trial

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, multinational phase 2 trial that aims to explore the use of molecular and clinical risk-directed therapy in treatment of children 0-4.99 years of age with newly diagnosed medulloblastoma.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2022-09-07; most recent amendment 2026-02-10.
Status change: Not Yet Recruiting → Recruiting 2022-09-16
Trial Details
NCT Number NCT05535166
Lead Sponsor St. Jude Children's Research Hospital
Collaborators: National Cancer Institute (NCI)
Conditions Medulloblastoma
Enrollment 130 participants
Start Date 2022-12-20
Primary Completion 2035-07 (estimated)
Study Completion 2035-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-12